Journal: Vaccines
Article Title: A Precision-Engineered DC-Targeting mRNA-LNP Neoantigen Vaccine Elicits Stronger T Cell Responses and Exhibits Superior Tumor Control
doi: 10.3390/vaccines14030239
Figure Lengend Snippet: Transfection, cytotoxicity, and biodistribution of mRNA-LNP complexes. ( A ) Cytotoxicity of Mal-LNP and Nb-LNP in mCLEC9A + HEK-293T cells. Cell viability evaluated using Cell Titer Luminescent Cell Viability Assay kit 24 h after treatment with mRNA Mal-LNP or Nb-LNP. ( B , C ) Time-course quantification of bioluminescence resulted from treating mCLEC9A + HEK-293T cells and FL-DCs derived from mouse bone marrow with mRNA Mal-LNP or Nb-LNP at 0.5 μg/mL ( n = 5). ( D ) Ex vivo imaging of organs was performed 4 h after injection. Shown are representative bioluminescence images and quantification of bioluminescence signals from organs extracted from C57BL/6 mice following intramuscular administration of 5 μg luciferase (Luc) formulated in either Mal-LNP or Nb-LNP. Abbreviations: LN, lymph node; Li, liver; S, spleen; Lu, lung; K, kidney. ( E , F ) Quantification of eGFP + cells in distinct cell subsets in spleen and lymph nodes 36 h after mice were treated intramuscularly with 10 μg eGFP mRNA-LNP. Statistical analyses were performed using two-way ANOVA. All results are presented as mean ± SEM. “ns”, no significant difference; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
Article Snippet: Human embryonic kidney epithelial 293T cell line was purchased from ATCC (CAT.CBP60439, RRID: CVCL_0063, Manassas, VA, USA).
Techniques: Transfection, Cell Viability Assay, Derivative Assay, Ex Vivo, Imaging, Injection, Luciferase